Pneumovax 23 Shortage: What Providers and Prescribers Need to Know in 2026

Pneumovax 23 Supply Constraints: A Provider Briefing for 2026

If your patients are reporting difficulty obtaining Pneumovax 23 (PPSV23), the problem is real. Intermittent supply constraints have affected this vaccine for several years, and as of early 2026, availability remains inconsistent across pharmacy channels and geographic regions.

This briefing covers what you need to know as a prescriber or clinical decision-maker: the supply timeline, implications for your practice, current alternatives, cost and access considerations, and tools that can help your patients navigate the situation.

Supply Timeline: How We Got Here

Pneumovax 23, manufactured exclusively by Merck & Co., has experienced periodic supply disruptions since approximately 2019. Key milestones include:

• 2019–2020: Initial supply constraints reported, attributed to manufacturing capacity limitations and increased seasonal demand.
• 2021–2022: Some improvement in supply, though spot shortages persisted at individual pharmacy and clinic level.
• 2023–2024: A more significant shortage period, with the FDA drug shortage database listing Pneumovax 23 as supply-limited. Merck cited manufacturing complexity and high demand as contributing factors.
• 2025–2026: Supply has improved relative to 2023–2024 peak shortage, but intermittent stockouts continue, particularly at chain pharmacies and in rural and underserved areas.

As of February 2026, Pneumovax 23 is not listed as discontinued. Merck continues production and distribution, but supply is not consistently meeting demand across all channels.

Prescribing Implications

The ongoing supply variability has several implications for clinical practice:

Patient Completion of Vaccine Series

Patients who received PCV15 (Vaxneuvance) and are due for a follow-up dose of PPSV23 may face delays. Per ACIP guidelines, PPSV23 should be administered at least 8 weeks after PCV15 for most adults, or at least 1 year later for immunocompromised patients. If PPSV23 is unavailable at the scheduled follow-up, providers should:

• Document the delay and reason in the patient's chart
• Set a recall or follow-up reminder for when supply becomes available
• Reassure patients that the delay, while not ideal, does not negate the protection from their PCV15 dose

New Patients: PCV20 as a Streamlined Alternative

For pneumococcal vaccine-naïve adults, the simplest approach in the current supply environment may be to prescribe Prevnar 20 (PCV20) as a single-dose option. This eliminates the need for a follow-up PPSV23 dose entirely and is consistent with current ACIP recommendations.

This is particularly relevant for:

• Adults 65 and older with no prior pneumococcal vaccination
• Adults 19–64 with qualifying chronic conditions or immunocompromising conditions
• Settings where minimizing follow-up visits is advantageous (e.g., patients with transportation barriers, those at risk of loss to follow-up)

Revaccination Considerations

For patients due for PPSV23 revaccination (e.g., those who received their first dose 5+ years ago and meet criteria for a second dose), the same supply constraints apply. If PPSV23 is unavailable, document the situation and plan for administration when supply allows.

Current Availability Picture

Availability varies significantly by:

• Pharmacy type: Independent pharmacies and hospital outpatient pharmacies may have stock when chain pharmacies do not, due to different distributor relationships.
• Geography: Urban areas generally have better supply than rural regions. Health departments in some states maintain dedicated vaccine stocks.
• Seasonality: Supply tends to be tightest in fall and early winter when vaccination campaigns peak, with better availability in spring and summer.

Providers can direct patients to Medfinder for Providers to help locate Pneumovax 23 inventory in their area.

Cost and Access Considerations

For insured patients, Pneumovax 23 is typically covered at no cost:

• Medicare Part B covers all ACIP-recommended pneumococcal vaccines with $0 patient cost-sharing.
• Private insurance under ACA-compliant plans covers ACIP-recommended vaccines without cost-sharing.
• Medicaid coverage varies by state but generally includes pneumococcal vaccines.

For uninsured patients, the cash price ranges from approximately $100 to $250 per dose. Options to reduce cost include:

• Merck Vaccine Patient Assistance Program for eligible uninsured patients
• Local health department immunization clinics that may offer vaccines at reduced or no cost
• Federally Qualified Health Centers (FQHCs) that provide vaccines on a sliding fee scale
• Vaccines for Children (VFC) program for eligible pediatric patients

Tools and Resources for Your Practice

Several resources can help you and your patients navigate the Pneumovax 23 supply situation:

• Medfinder for Providers: A pharmacy availability search tool that helps locate vaccines and medications in stock near your patients. Share this with patients who are struggling to find Pneumovax 23.
• FDA Drug Shortage Database: Check current shortage status at accessdata.fda.gov.
• CDC Pneumococcal Vaccination Recommendations: Current ACIP guidelines for pneumococcal vaccine use in adults and children.
• Merck Medical Affairs: For clinical questions about Pneumovax 23 supply or formulation, contact Merck's medical information line.

Looking Ahead

The pneumococcal vaccine landscape continues to evolve. Key developments to watch:

• Expanded conjugate vaccine coverage: As PCV20 adoption increases, the population requiring PPSV23 may narrow, potentially easing demand pressure.
• Pipeline vaccines: Higher-valent conjugate vaccines are in development that may further reduce reliance on PPSV23.
• Merck production capacity: Merck has indicated ongoing investment in manufacturing capacity, which may improve supply stability over time.

In the meantime, the most practical approach is to use PCV20 for vaccine-naïve patients when possible, maintain recall systems for patients awaiting PPSV23, and direct patients to tools like Medfinder to locate available supply.

Final Thoughts

The Pneumovax 23 shortage is a supply-side challenge, not a clinical obsolescence issue. PPSV23 remains an important vaccine for specific patient populations, particularly those who have already started the PCV15 + PPSV23 sequence. By staying informed about availability, leveraging alternatives where appropriate, and using tools to help patients locate supply, you can ensure your patients maintain protection against pneumococcal disease.

For patient-facing resources to share with your practice, see our guides on finding Pneumovax 23 in stock and Pneumovax 23 alternatives.